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ANALISIS EKSPRESI OTUB1 DI DALAM SEL BARAH PAYUDARA MCF7 
DAN SEL EPITHELIUM PAYUDARA MANUSIA MCF10A 
ABSTRAK 
Proses pasca translasi modifikasi (PTM) protein diketahui memainkan peranan 
yang penting di dalam fungsi protein. Ubiquitinasi merupakan salah satu proses PTM 
yang penting di mana molekul ubiquitin ditambah ke protein target oleh enzim pengaktif 
ubiquitin (E1), enzim konjugat ubiquitin (E2) dan ubiquitin ligase (E3). Proses ini boleh 
diterbalikkan oleh tindakan enzim khusus yang dikenali sebagai enzim deubiquitinasi 
(DUBs). OTUB1 merupakan DUBs yang dilaporkan mempunyai peranan penting di 
dalam permulaan dan perkembangan barah. Untuk menyiasat peranan OTUB1 di dalam 
barah payu dara, kajian awal dijalankan untuk membandingkan ekspresi OTUB1 di dalam 
sel barah payudara MCF7 dan sel epithelium payudara manusia MCF10A.  Ekspresi 
OTUB1 di dalam MCF7 dan MCF10A dianalisis menggunakan quantitatif PCR dan nilai 
pengkuantitian relatif yang diperoleh menggunakan kaedah ΔΔCt. Ujian Mann-Whitney 
digunakan untuk melihat perbezaan ekspresi OTUB1 di antara MCF7 dan MCF10A. 
Untuk menyokong kajian qPCR ini, analisis bioinformatik dilakukan  menggunakan 
maklumat mikrodatasusunan daripada Gene Expression Omnibus (GEO) 
(https://www.ncbi.nlm.nih.gov/geo/). Analisis qPCR menunjukkan bahawa ekspresi 
OTUB1 secara signifikan adalah lebih tinggi di dalam MCF7 berbanding dengan 
MCF10A (p = 0.037). Penemuan ini disokong oleh analisis bioinformatik daripada 
maklumat mikrodatasusunan GEO yang terpilih di mana hampir kesemua prob OTUB1 
telah mengesahkan bahawa ekspresi OTUB1 lebih tinggi di dalam MCF7 secara 
signifikan. Justeru, kajian pada masa akan datang perlu dilakukan untuk mendedahkan 
peranan serta fungsi kompleks OTUB1 dalam jejak laluan berkaitan kanser. 
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ANALYSIS OF OTUB1 EXPRESSION IN HUMAN BREAST 
ADENOCARCINOMA CELL LINE MCF7 AND HUMAN BREAST 
EPITHELIAL CELL LINE MCF10A 
ABSTRACT 
Post-translational modification (PTM) of protein is known to play a major role in 
protein function. One of the most important PTM is ubiquitination, in which the ubiquitin 
molecule(s) are added to a target protein by ubiquitin activating enzymes (E1s), ubiquitin 
conjugating enzymes (E2s) and ubiquitin ligases (E3s). This process is reversible by the 
action of specialized enzymes known as deubiquitinases (DUBs). OTUB1 is a DUBs that 
was reported to has critical roles in cancer initiation and progression. To investigate the 
role of OTUB1 in breast cancer, this preliminary study was conducted to compare the 
expression of OTUB1 in human breast adenocarcinoma cell line, MCF7 and human 
epithelial cell line, MCF10A. Expression of OTUB1 in MCF7 and MCF10A was 
analysed by quantitative real-time PCR and relative quantification (RQ) value was 
obtained using ΔΔCt method. Mann-Whitney test was used to evaluate the differences in 
OTUB1 expression levels between MCF7 and MCF10A. To support our qPCR study, 
computational analysis was also performed on selected microarray datasets from Gene 
Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/). qPCR 
analysis shows that OTUB1 expression was significantly higher in MCF7 compared to 
MCF10A (p = 0.037).  Computational analysis on selected GEO microarray datasets 
shows that almost all probes corresponding to OTUB1 confirmed that OTUB1 expression 
is significantly higher in MCF7. Therefore, further studies should be done to uncover the 
role and function of OTUB1 in cancer-associated pathways. 
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CHAPTER 1 
INTRODUCTION 
1.1 Research Background 
 
According to World Health Organization (WHO), breast cancer is among the most 
commonly diagnosed life-threatening cancer in women worldwide. Among Malaysian 
women, it is regarded as the most common cancer in all ethnic and age groups. Current 
breast cancer treatment includes surgery, radiotherapy, hormonal therapy and targeted 
therapy.  However, it is worth noting that there are always adverse effects associated with 
the treatment. Surgery can cause pain and lymphedema, as well as removal of the entire 
breast, including the normal tissue. In chemotherapy, hair loss, loss of appetite, fatigue, 
nausea and vomiting are very common side effects. Meanwhile, hormonal therapy causes 
headache, aches, hot flashes and night sweats.  
In contrast, less side effects were seen in targeted therapy. Targeted therapy can 
specifically kill cancer cells and usually does not attack the neighbouring healthy cells. 
Targeted therapy usually involves the use of drugs or other substances that suppress the 
molecular mechanism in cancer development and progression, for example by blocking 
the proliferation and promotion of cancer cell cycle regulation, inducing apoptosis or 
autophagy in cancer cells, and delivering substances that are toxic to cancer cells and kill 
them. Among the examples of breast cancer targeted drugs that have been developed 
including trastuzumab that target HER2 proteins (Swain et al., 2015), olaparib for BRCA 
mutations (Robson et al., 2017) and CDK4/6 inhibitor, palbociclib (Turner et al., 2015). 
Besides having less side effects than standard chemotherapy drugs, some targeted therapy 
can also facilitate other types of treatment for better outcome. Therefore, it is crucial to 
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find a good molecular target to develop targeted drug therapy for more effective 
treatments and greater survival rates. 
Deubiquitinating enzymes or DUBs is a component of the protein ubiquitination 
system that has been regarded as potential therapeutic target for cancer. In human body, 
there are at least 101 DUBs that can be categorized into seven families consisting of USP, 
UCH, OTU, MJD, JAMM, MINDY and ZUFSP. There is growing evidence that the 
dysregulation of human DUBs often leads to the development of many types of cancer. 
Some DUBs from USP family such as USP2, USP4, USP7, USP10 and USP29 are 
reported to regulate p53, one of the important tumour suppressor protein (Kon et al., 
2010). Moreover, DUBs are also known to control  several cancer signalling pathways, 
especially those mediated by  NFκB, TGF-β and WNT (Jung et al., 2013; Arcy et al., 
2015). Apart from signal transduction, some fundamental cellular processes such as cell 
cycle progression, apoptosis, and response to DNA damage are also regulated by DUBs 
(Jacq et al., 2013). These information show that altered expression of DUBs is very 
common in cancer development and progression and thus, DUBs are increasingly 
regarded as potential targets in cancer therapy (Hussain et al., 2009). 
Apart from the well-studied USP family DUBs, OTU family members have 
recently gaining attention as promising regulators in cancer related pathways. An OTU 
member known as OTUB1 was reported as a novel p53 regulator (Sun et al., 2012). Many 
studies also reported that OTUB1 has direct involvement in the development of various 
malignancies including breast cancer (Karunarathna et al., 2016), ovarian cancer (Wang 
et al., 2018), lung cancer (Baietti et al., 2016), prostate cancer (Iglesias-Gato et al., 2015), 
colorectal cancer (Zhou et al., 2014), gastric adenocarcinoma (Weng et al., 2016) and 
glioma (Xu et al., 2017). 
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1.2 Problem Statement 
Following studies that reported the emerging role of OTUB1 in many types of 
cancer, there is an increasing interest to study the effect of OTUB1 knockdown or 
overexpression in cancer cell lines with the aim to develop OTUB1 as targeted cancer 
therapy. However, due to diverse function of OTUB1, the expression pattern of OTUB1 
in breast cancer cell line remain unclear. For instance, interaction of OTUB1 with p53 is 
reported to increase apoptosis in cancer cell line while OTUB1 and c-IAP partnership 
would decrease apoptosis (Saldana et al., 2019). Therefore, it is essential to perform a 
preliminary analysis on the expression of OTUB1 in cancer and normal cells to fully 
understand the effects of OTUB1 on cancer before proceeding with any therapeutic 
studies.  
1.3 Objective of the Study 
This study aimed to compare the OTUB1 gene expression in human breast 
adenocarcinoma cells MCF7 (cancer cells) and human breast epithelial cell MCF10A 
(normal cells). At the end of this study, the expression level of OTUB1 in both cells can 
be compared for the purpose of further studies involving gene manipulation of OTUB1 
in cancer cell lines. The specific objectives were: 
1. to extract RNA from MCF7 and MCF10A cell lines. 
2. to synthesize cDNA using reverse transcription process. 
3. to analyze OTUB1 expression in MCF7 and MCF10A by Real-Time Polymerase 
Chain Reaction (qPCR). 
4. to perform a computational analysis and compare OTUB1 expression in MCF7 
and MCF10A using selected microarray datasets from Gene Expression Omnibus 
(GEO) database. 
4 
1.4 Hypothesis of the Study 
The expression level of OTUB1 in human breast adenocarcinoma cell line MCF7 
was higher than human breast epithelial cell line MCF10A. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Cancer statistic  
Cancer is regarded as the most common leading cause of death worldwide of all 
income levels (Ferlay, 2019). In 2018, there were at least 18.1 million new cases and 9.6 
million deaths reported (World Health Organization). Globally, in every five men and six 
women, at least one would develop cancer in their lifetime, and in every eight men and 
11 women, at least one would die because of cancer. 
The highest cancer incidence is contributed by lung and female breast cancers 
with 11.6% from the total cancer incidence, which is approximately 2.1 million 
diagnoses. This is followed by colorectal cancer with 10.2%, which is equal to 1.8 million 
reported cases. Other top cancers diagnosed are prostate cancer (1.3 million cases, 7.1%), 
and stomach cancer (1.0 million cases, 5.7%). 
In terms of death incidence caused by cancer, lung cancer contributed to the 
highest number of deaths with 1.8 million deaths (18.4%) followed by colorectal cancer 
with 881 000 deaths (9.2%). Stomach and liver cancer are responsible for the third leading 
cause of cancer death, accounting for 783 000 deaths (8.2%), and 782 000 deaths (8.2%) 
respectively. Figures 2.1 and 2.2 show number of new cases and death caused by cancer 
in 2018. 
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Figure 2.1 Number of new cancer cases in 2018 in both sexes and 
all ages. Source: GLOBOCAN. 
Figure 2.2 Number of deaths caused by cancer in 2018, in both 
sexes and all ages. Source: GLOBOCAN. 
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2.2 Breast cancer 
Globally, breast cancer is among the most commonly diagnosed cancer in women, 
accounting for approximately one in four of all newly diagnosed cancer cases. Moreover, 
breast cancer is also reported as the most common cancer in 154 of the 185 countries 
listed in Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2018. From 
all the new breast cancer cases diagnosed worldwide in 2012, more than 600,000 (39%) 
new cases were reported in Asia alone (Fan et al., 2015). Breast cancer is also regarded 
as the most common cancer in all ethnic groups and all age groups among Malaysian 
women. Thirty out of 100 women who suffer from cancer in Malaysia are breast cancer 
patients (Lim and Yahaya, 2002). Based on the study by Hisham and Yip (2004), more 
than half of the breast cancer patients in Malaysia were Malay (53.8%) followed by 
Chinese (27.1%), Indian (9.6%), other ethnic group (7.7%) and foreigners (1.9%).  
There are several ways of treating breast cancer such as surgery, radiotherapy, 
hormonal therapy and targeted therapy. Surgery is done by removing the cancer tissue as 
well as some surrounding normal tissue. Sometimes, the entire breast is removed in a 
procedure called mastectomy. Surgery is not only invasive but women who want to 
recreate a bulge to replace the removed breast must undergo another surgery for breast 
reconstruction. Radiotherapy is a treatment with high doses of radiation to destroy the 
cancer cells. The patients usually experience fatigue, redness, skin irritation and dryness 
at the targeted area. For chemotherapy, anti-cancer drugs are given to the patients 
intravenously or in the form of pills to stop or reduce the proliferation rate of cancer cells. 
It is considered a systemic therapy, in which drugs are spread throughout the body to treat 
cancer cells. Therefore, chemo drugs not only rapidly attack growing cancer cells, they 
also affect healthy growing cells. In chemotherapy, patients may experience sides effects 
such as loss of appetite, nausea and vomiting (Toprak et al., 2018). Several blood forming 
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cells in bone marrow are also damaged. Thus, patients experience fatigue, easily bleed 
and bruise, and are susceptible to infections. 
Some breast cancer growth is stimulated by the hormones in the body such as 
progesterone or estrogen. These types of cancers are known as hormone receptor-positive 
cancers. Hormone therapy works by blocking the hormones from acting on cancer cells 
or decreasing the hormone levels. Fulvestrant is one of the drugs that block and 
permanently degrades the estrogen receptor on breast cancer (Osborne et al., 2004). 
However, patients who are taking this drug experience some side effects such as 
headache, bone pain, hot flashes and night sweats.  
In contrast to chemotherapy, targeted therapy does not attack all the cells 
including healthy cells. Targeted cancer therapy involves drugs or other substances that 
block the proliferation and promotion of cell cycle regulation of the cancer cells. Besides, 
targeted therapy also induces apoptosis or autophagy and destroying the cancer cells by 
delivery of toxic substances specifically to cancer cells (Padma, 2015). Examples of 
breast cancer targeted drugs that have been developed include trastuzumab, which targets 
HER2 proteins (Swain et al., 2015), olaparib for  BRCA mutations (Robson et al., 2017) 
and CDK4/6 inhibitor, palbociclib (Turner et al., 2015). 
Targeted therapy usually have less s side effects than chemotherapy drugs (Vega 
et al., 2012) and some targeted therapy  can facilitate other treatments for better result. 
Therefore, it is crucial to find a good target to develop targeted drug therapy for more 
effective treatments and greater survival rates.  
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2.3 Protein Ubiquitination 
Ubiquitin is a small molecule of 76-amino acid polypeptide encoded on multiple 
genes. It is highly conserved among many species and expressed in all eukaryotes. 
Ubiquitination is a process of attaching this ubiquitin molecules to other protein 
(substrate) through a complex, specific and highly regulated process (Fang and 
Weissman, 2004). Three enzymes are involved in catalyzing the ubiquitination process; 
E1 ubiquitin activating enzyme, E2 ubiquitin conjugating enzyme, and two types of E3 
ubiquitin ligase called HECT and RING. These three enzymes are known to work in a 
hierarchical manner. In ubiquitination process, the ubiquitin molecules are firstly 
activated by E1 through an ATP dependent step. E1 forms a thiol ester bond between its 
active cysteine and the ubiquitin’s C terminus before transferring this activated ubiquitin 
to the E2’s active site cysteine residue. Lastly, the ubiquitin is transferred to the substrate 
(or other ubiquitin)’s lysine residue to form a mono- or polyubiquitin chain on the 
substrate (Hershko and Ciechanover, 1998; Pickart and Eddins, 2004). The ubiquitin 
functions as a ‘tag’ or label’ for its substrate, in which every ubiquitinated substrates is 
assigned to perform specific function according to the type of ubiquitin chain. For 
example, substrates that are ubiquitinated with four ubiquitin molecule 
(polyubiquitination) at their Lys48 destroy themselves through proteasomal degradation, 
while substrates that are ubiquitinated at their Lys63 will enter DNA damage process 
(Mcclurg and Robson, 2015; Chen, 2016; He et al., 2016). 
 Ubiquitination is a reversible process. Apart from E1, E2 and E3, a set of enzymes 
known as deubiquitinases (DUBs) is specifically tasked to counter protein ubiquitination 
(D’Arcy et al., 2015; Suresh et al., 2015; Coyne and Wing, 2016; Pinto-fernandez and 
Kessler, 2016). The DUBs function to remove the covalent attachment between ubiquitin 
10 
molecules or ubiquitin-substrates thus rescuing the substrates from their fates assigned by 
ubiquitination process. 
  
11 
 
 
 
Figure 2.3 Process of ubiquitination. Ubiquitination occurs as a result of the sequential 
action of three different enzymes, ubiquitin activating enzyme (E1), ubiquitin conjugating 
enzyme (E2), and ubiquitin protein ligase (E3). (Extracted from Maupin-Furlow (2014)). 
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2.4 The Deubiquitinating Enzymes 
The ubiquitin system is catalyzed by two E1s, about 35 E2s and more than 600 
E3s to confer specificity for substrate ubiquitination and diversity to ubiquitin chains  
(Chaugule and Walden, 2016). To counter the highly specific ubiquitination process, 101 
deubiquitinases (DUBs) from various families are involved in the de-ubiquitination 
process. DUBs can be categorized into seven families based on sequence and structural 
similarities which are ubiquitin-specific proteases (USPs), ovarian tumor domain 
proteases (OTUs), ubiquitin carboxy-terminal hydrolases (UCHs), JAB1/MPN/MOV34 
domain associated metallopeptidases (JAMMs), Machado-Joseph disease protein domain 
proteases (MJDs), and newly identified motif interacting with Ub-containing novel DUB 
family (MINDYs) and zinc finger with UFM1 specific peptidase domain (ZUFSPs) 
(Nijman et al., 2005; Mevissen and Komander, 2017). USPs, UCHs, OTUs, MJDs and 
the novel MINDYs and ZUFSPs families belong to thiol proteases, while JAMMs, are 
Zn2+ metalloproteases (Arif et al., 2016; Kwasna et al., 2018). These DUBs vary in size, 
characteristics, specificity and have different spectrum of substrates or interacting protein 
(Mevissen and Komander, 2017). 
The most essential role of DUBs is their ability to specifically remove ubiquitin 
from target proteins (Fraile et al., 2012). Since ubiquitination govern nearly every process 
in human cellular system, DUBs have a great influence on many biological processes and 
cellular pathways (He et al., 2016; Kee and Huang, 2016). Recently, DUBs have been  
the subject of intensive research  closely linked to human disease (Mevissen et al., 2013). 
This is supported by Clague and colleague (2012) who reported that many of the DUBs 
are predicted to have implications in human diseases such as neurological diseases and 
cancer. In relation to cancer, abnormality in DUB signalling and activity can play 
important roles in cancer development, progression and metastasis. This is because DUBs 
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are known to regulate cellular growth, survival and homeostasis, which are closely related 
to cancer, through multiple pathways including epigenetics. (Mcclurg and Robson, 2015). 
Studies by Luise et al. (2012) show that many DUBs are associated with tumours due to 
alterations in gene or protein expression levels. For example, various breast cancers 
showed an increase in expression level of USP7, UCH37, OTUD6B, VCPIP1 and 
COPS5. Meanwhile, oncogenic protein USP6 is found to be overexpressed in primary 
aneurysmal bone cyst (ABC) (Ye et al., 2010). Therefore, exploration of the in-depth 
mechanism by which DUBs regulate cancer-associated pathways could provide new 
insight in cancer therapeutics strategy. 
2.5 OTUB1 
The OTU family comprises a group of cystine protease homologous to the ovarian 
tumor gene product of Drosophila Melanogaster (Makarova et al., 2000). In the human 
genome, OTU domains exist in at least 18 genes (Mevissen et al., 2013). Examples of 
deubiquitinating enzymes in OTU family are OTUB1, OTUB2, OTUD1, OTUD3, 
OTUD4, OTUD5, OTUD6A, OTUD6B, OTUD7, YOD1, OTULIN, A20, Cezanne, 
Cezanne2, TRABID and VCPIP1 (Coyne and Wing, 2016). OTUB1, the most well-
known member in the OTU family  was discovered  in 2003 (Balakirev et al., 2003). This 
protein is reported  to have the ability to cleave the iso-peptide bond within polyubiquitin 
chains, with a preference target to polyubiquitin chain joined by Lys48 (Edelmann et al., 
2009). 
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2.6 OTUB1 in cancers 
A growing number of studies demonstrate that OTUB1 has a critical role in cancer 
development and progression by regulating apoptosis, therapeutic resistance, 
proliferation, migration and invasion in several cancer types (Saldana et al., 2019). 
However, it should be noted that OTUB1 might have a complex effect in different types 
of malignancies because it regulates the expression and activity of many substrates and 
participates in multiple cell signalling pathways (Nakada et al., 2010). 
According to  Baietti et al (2016),  the deubiquitinase OTUB1 promotes lung 
cancer formation and is associated with poor patient prognosis. In breast cancer, OTUB1 
prevents the proteasomal degradation of FOXM1 upon epirubicin treatment and regulates 
the expression of FOXM1. FOXM1 is known to be involved in therapeutics resistance 
across many tumour types, thus, its stabilization by OTUB1 could enhance the 
proliferative rate and treatment resistance of breast cancer cells (Karunarathna et al., 
2016). Overexpressed OTUB1 in ovarian cancer also interacts  with FOXM1, which 
suggests promotion of tumorigenesis and tumour progression (Wang et al., 2016 ).  
In gastric adenocarcinoma patients, cells expressing higher levels of OTUB1 are 
correlated with adverse clinicopathological features and lower survival rates. In vitro 
experiments further suggest that OTUB1 promotes tumour progression by enhancing 
tumour cell migration and invasion (Weng et al., 2016). In addition, research by Zhou et 
al. (2014) demonstrate that OTUB1 promotes the migration, invasion, and metastasis of 
colorectal cancer cells in vitro and in vivo, and could potentially be developed as a 
metastasis marker and prognostic factor in colorectal cancer. This study is also supported 
by Liu et al. (2014). 
  It is also reported that OTUB1 expression is elevated in hepatocellular carcinoma 
and plays an important role in tumour recurrence, tumour cell migration and invasion (Ni 
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et al., 2017). Research done by Iglesias-Gato et al. (2015) shows that OTUB1 protein is 
highly expressed in prostate cancer and induces cell invasion through a RhoA-mediated 
mechanism. 
2.7 OTUB1 as p53 regulator 
p53 is a tumour suppressor that plays a crucial role in maintaining genome 
stability and preventing organisms from getting cancer (Oren, 2003). The main function 
of p53 is to act as a transcription factor to activate or repress many  genes, including genes 
that are involved in the three major DNA damage responses which are DNA damage 
repair, cell cycle arrest and apoptosis (Vogelstein et al., 2000). Loss of p53 function 
through genetic mutations or alterations in the p53 regulatory networks is observed in 
most  human cancers (Soussi et al., 2000).  
While a majority of the studies point to a tumorigenic role for OTUB1, research 
published by Sun et al., (2012) indicates that OTUB1 promotes apoptosis in osteosarcoma 
and lung non-small cell carcinoma cell lines in a p53-dependent manner. They discovered 
that OTUB1 is directly bound and weakly deubiquitinates p53, which may further 
enhance OTUB1-mediated p53 stabilization. Apart from that, OTUB1 also inhibits 
MDM2-mediated ubiquitination of p53 in a non-canonical manner to promote its 
stabilization. In this case, OTUB1 blocks MDM2-medited p53 ubiquitination by binding 
with UbcH5, an E2 conjugating enzyme for MDM2. The inhibition of UbcH5 prevents 
ubiquitin conjugating step in ubiquitination of p53 and thus, rescues p53 from 
proteasomal degradation. 
Generally, MDM2 is an oncoprotein that functions to maintain a low p53 
expression level in human cells. It does so by binding  with the p53 N-terminal 
transactivation domain, directly inhibiting its transcriptional activity (Chen et al., 1993). 
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Besides direct inhibition, MDM2 also regulates p53 levels by promoting ubiquitination 
on p53 that leads to its degradation through the proteasome system (Haupt et al., 1997; 
Kubbutat et al., 1997). Using these two mechanisms, MDM2 efficiently suppresses cell 
growth arrest and apoptosis mediated by p53. However, some DUBs such as OTUB1 can 
counteract the ubiquitination process and rescue the p53 from proteasomal degradation 
and thus, promote apoptosis in cancer cells (Hock et al., 2011; Yuan et al., 2011). 
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Figure 2.4 A schematic diagram for OTUB1 regulation of p53 ubiquitination. Otub1 
suppresses p53 ubiquitination in the cytoplasm primarily by non-canonical inhibition of 
UbcH5/MDM2 activity, while it may also possess weak canonical DUB catalytic activity 
to deubiquitinate p53. Arrow indicates activation, whereas bar indicates inhibition (Sun 
et al., 2012). 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Materials 
MCF7 and MCF10A were purchased from American Type Culture Collection 
(ATCC), USA. Dulbecco’s Modified Eagle Medium (DMEM), DMEM/Nutrient Mixture 
F-12 (DMEM/F12), FBS, penicillin-streptomycin, horse serum, recombinant human 
epidermal growth factor (hEGF), insulin and trypsin express were from Gibco, USA. 
Hydrocortisone and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich, USA. All 
plasticware were from Greiner Bio-One, USA.  
 All primers and oligos were commercially synthesized by IDT, USA. TRIzol 
reagent was from Life Technologies, USA. Agarose, DNA 1kb ladder and loading dye 
were purchased from Thermo Fisher Scientific, USA. Ethidium bromide and TAE buffer 
were obtained from Sigma Aldrich, USA. QuantiNova Reverse Transcription kit and 
QuantiNova SYBR Green PCR kit were from Qiagen, USA. Tissue culture flasks and 
dishes were from JET Biofil, China. Other plasticware were from Greiner Bio-One, USA. 
3.2 Methods 
3.2.1 Cell Culture  
A proper aseptic area, technique and sterile handling were required for cell culture 
work. Biosafety cabinet was sanitized using 70% alcohol as well as other materials and 
equipment such as media bottles, pipette and tips boxes. Autoclavable materials were 
autoclaved at 121 °C for 30 minutes at 100 kPa prior to use. 
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3.2.1.1 Maintaining Cells 
MCF7 human breast cancer cell lines and MCF10A human breast epithelial cell 
lines were chosen for this study to represent cancer cells (MCF7) and normal cells 
(MCF10A).  MCF7 was grown in DMEM supplemented with 10% (v/v) FBS and 1% 
(v/v) penicillin-streptomycin. Meanwhile, MCF10A were maintained in DMEM/F12 in 
suspension and supplemented with 5% (v/v) horse serum, 20 ng/ml of hEGF, 0.5 µg/ml 
of hydrocortisone, 10 µg/ml of insulin and 1% (v/v) penicillin-streptomycin. 
3.2.1.2 Thawing of Cells 
The cryopreserved MCF7 and MCF10A in liquid nitrogen tank were taken out 
and immediately submersed in a water bath at 37°C until cells become semi fluid. The 
cells were transferred into 5 ml of pre-warmed complete DMEM or DMEM/F12 in 15 ml 
tube and were mixed gently. The cells suspension was centrifuged at 2000 rpm for 5 
minutes. The supernatant was discarded, and the pellet was resuspended with pre-warmed 
complete media. The cell suspension was transferred into 25 cm2 tissue culture flask and 
incubated at 37°C in 5% CO2. Cells were routinely checked under inverted microscope 
to observe the confluency of cells growth. The cells were subcultured when they reached 
70 to 80% confluency. 
3.2.1.3 Sub-culturing of Cells 
Media was removed from the flasks and MCF7 and MCF10A cells were detached 
from the flask by incubating the cells in 3 ml of trypsin express for 5 to 10 minutes in 5% 
CO2 air at 37 °C. Then, the flask was gently tapped to detach the cells from the flask’s 
wall. 5 ml complete medium was added to the trypsinized cells. The cells suspension was 
transferred into the 15 ml tube and centrifuged for 5 minutes at 2000 rpm. The supernatant 
was discarded, and the pellet was resuspended with complete media. The cells were 
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transferred into a new 25 cm2 tissue culture flask and incubated in humidified incubator 
(Thermo Fisher Scientific, USA) at 37 °C in 5% CO2. 
3.2.1.4 Freezing Cells 
Cryopreservation was done to preserve MCF7 and MCF10A stocks. Cells were 
trysinized, detached, collected and pelleted by centrifugation at 2000 rpm for 5 minutes. 
Then, the cell pellet was resuspended in 1 ml fresh growth media. DMSO was added to 
the cell suspension at a final concentration of 10 % to prevent formation of ice crystals 
and fragmentation of the cell membrane. Finally, the cell stock was transferred into 
cryovials and stored at -80°C. 
3.2.2 Molecular Biology 
3.2.2.1 RNA Extraction 
MCF7 and MCF10A were grown in a 3.5 cm culture dish (10 cm2) until reached 
80% of confluency. Total RNA was isolated from cells using TRIzol reagent according 
to manufacturer’s protocol. In brief, growth media were aspirated and replaced with ice-
cold PBS to wash cells. 1 ml TRIzol reagent was added directly to the cells to lyse the 
cells and was pipetted up and down several times to homogenize the cells lysate. The cell 
lysate was transferred to 1.5 ml Eppendorf tube and incubated at room temperature for 5 
minutes. Then, 0.2 ml of chloroform was added, and the tube was shaken vigorously 
before being centrifuged at 12 000 × g for 15 minutes at 4 °C to extract RNA from the 
upper translucent aqueous layer. The aqueous layer was transferred to fresh tube and 0.5 
ml isopropyl alcohol was added to precipitate RNA. The mixture was vortexed and 
incubated at room temperature for 10 minutes. Then it was centrifuged at 12 000 × g for 
10 minutes at 4 °C. The precipitated RNA was pelleted, washed with 1 ml of 75 % ethanol 
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and centrifuged again at 7500 × g for 5 minutes at 4 °C. The supernatant was removed 
completely, and the pellet was left to air dry until it became translucent. RNA pellet was 
then resuspended in RNase-free water and incubated in heat block at 57 °C for 13 minutes. 
Then, the tubes were placed on ice and the RNA concentration were measured using 
Nanodrop 2000c (Thermo Fisher Scientific, USA). 
3.2.2.2 Checking RNA Integrity 
RNA integrity of the extracted RNA was checked by using gel electrophoresis. 
1.0 % (w/v) agarose gels were prepared by adding 0.5 g of agarose into 50 ml 1x TAE 
buffer and boiled in a microwave until completely dissolved. Gel mixture was left to cool 
before adding 2.5 μl of liquid ethidium bromide. Gel mixtures was poured into the casting 
tray and allowed to solidify for 1-2 hours at room temperature. After that, the gel is 
submerged in 1x TAE buffer in an electrophoresis tank. 2 μl of RNA suspension were 
mixed with 0.5 μl loading dye before being loaded into the wells. The electrophoresis was 
performed at 90 V for 45 minutes before visualising RNA bands using UV 
Transilluminator and Infinity Image Software (Vilber Lourmat, France). 
3.2.2.3 cDNA synthesis 
Reverse transcription of RNA was performed on Thermal Cycler (Bio-Rad, USA) 
using QuantiNova Reverse Transcription kit. The synthesis of cDNA was done using the 
RNA template extracted in 3.2.2.1. The process of cDNA synthesis comprises of two 
main steps; genomic DNA (gDNA) elimination and reverse transcription reaction. The 
gDNA reaction mixture was prepared as in Table 3.1 in Eppendorf tube, incubated at 45 
°C for two minutes and placed on ice immediately. Then, reverse transcriptase and reverse 
transcription was added to the mixture for the second reaction (reverse transcription 
reaction). The details for the second reaction are shown in Table 3.2. The mixture was 
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then incubated to anneal at 25 °C for three minutes, at 45 °C for 20 minutes for reverse 
transcription and inactivation of reaction at 85 °C for five minutes. 
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Table 3.1 Composition of genomic DNA elimination. 
Components Volume 
gDNA Removal Mix 
RNA Template 
RNase-free water 
2 µl 
Variable 
Variable 
Total reaction volume 15 µl 
 
 
 
Table 3.2 Composition of reverse transcription reaction. 
Components Volume 
Reverse Transcriptase 
Reverse Transcription Mix 
RNA Template 
1 µl 
4 µl 
14 µl 
Total reaction volume 20 µl 
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3.2.2.4 Verification of cDNA synthesis 
Verification of cDNA synthesis was achieved by amplification of house-keeping 
gene, β-actin. β-actin forward (5’ AGAGCTACGAGCTGCCTGAC 3’) and reverse (5’ 
AGCACTGTGTTGGCGTACAG 3’) primers were commercially synthesized. The 
reaction mixture is as shown in Table 3.3 and PCR reaction was set up as in Table 3.4. 
The PCR product was then subjected to electrophoresis. Agarose gel was prepared as 
mentioned in 3.2.2.2. Then, 10 μl of RNA suspension with 2.5 μl loading dye was loaded 
into each well. 5 μl of 1kb plus ladder were loaded into the first lane to serve as a marker 
to determine the size of the PCR product. Electrophoresis was performed at 100 V for 45 
minutes before visualizing RNA bands using UV Transilluminator and Infinity Image 
Software (Vilber Lourmat, France). 
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Table 3.3 Compositions of PCR reaction. 
Components Volume 
cDNA template 
Primer (β-actin) 
Taq 2x Master Mix 
RNase-Free Water 
1 µl 
0.5 µl 
12.5 µl 
11 µl 
Total reaction volume 25 µl 
 
Table 3.4 Reaction steps in PCR. 
Step Time Temperature Cycle 
Initial 30 seconds 95 °C 1 
Denaturation 
Annealing 
Extension 
30 seconds 
60 seconds 
2 minutes 
95 °C 
55 °C 
68 °C 
 
30 
Final Extension 5 minutes 68 °C 1 
 
  
